Sputnik-V, Coronavirus vaccine of Russia, has shown 91.4% efficacy based on data analysis of the final control point of clinical trials.

Russia's COVID-19 vaccine Sputnik-V show 91.4% efficacy based on data analysis

Russia has become the first country to start its inoculation drive. Medical workers and teachers, who are two high-risk groups, are among the first to get shots of COVID-19 vaccine.

Russia becomes first country to vaccinate citizens outside trials

Russia's coronavirus vaccine Sputnik-V has arrived in India for adapted phase 2 & 3 clinical trials. This comes after both countries agrees to mass produce the vaccine in India.

Sputnik-V arrives in India for phase 2 & 3 clinical trials

Russia on Friday reported 12,126 new <a href="https://www.wionews.com/world/spain-invokes-state-of-emergency-over-madrid-lockdown-as-europe-grapples-with-virus-334020">coronavirus</a> cases taking the total number of cases to 1,272,238 as authorities contemplate closing bars and nightclubs.

<a href="https://www.wionews.com/world/massive-lockdowns-punishing-for-communities-and-society-who-334120">Also Read |&nbsp;Massive lockdowns punishing for communities and society: WHO</a>

Amid the virus surge, authorities have told residents to stay home over the weekend as Kremlin said there were no plans to impose a lockdown although it said authorities at the regional level would decide on measures to curb the virus.

The virus surge comes as Russia announced it would begin administring the Sputnik V vaccine on a mass scale this month. Putin had said earlier that "around 50 people" in his inner circle had been vaccinated.

Authorities have asked those over the over the age of 65 to isolate themselves even as 201 COVID-19 related deaths were reported on Friday with the total death toll climbing to &nbsp;22,257.

Moscow which was the epicentre of the virus earlier has made it mandatory to wear masks. Mayor Sergei Sobyanin has asked employers to allow third of its staff to work remotely. Russia had ordered a strict lockdown in March but began lifting restrictions as cases began to drop in May.

Moscow, however, reimposed some tough measures last month. Russia now has the fourth-highest confirmed cases of coronavirus in the world.

Russia on Friday reported 12,126 new coronavirus cases taking the total number of cases to 1,272,238 as authorities contemplate closing bars and nightclubs. Also Read | Massive lockdowns punishing for communities and society: WHO Amid the virus surge, authorities have told residents to stay home over the weekend as Kremlin said there were no plans to impose a lockdown although it said authorities at the regional level would decide on measures to curb the virus.

Russia on Friday reported 12,126 new coronavirus cases taking the total number of cases to 1,272,238 as authorities contemplate closing bars and nightclubs. Also Read | Massive lockdowns punishing for communities and society: WHO Amid the virus surge, authorities have told residents to stay home over the weekend as Kremlin said there were no plans to impose a lockdown although it said authorities at the regional level would decide on measures to curb the virus. The virus surge comes as Russia announced it would begin administring the Sputnik V vaccine on a mass scale this month. Putin had said earlier that "around 50 people" in his inner circle had been vaccinated. Authorities have asked those over the over the age of 65 to isolate themselves even as 201 COVID-19 related deaths were reported on Friday with the total death toll climbing to 22,257. Moscow which was the epicentre of the virus earlier has made it mandatory to wear masks. Mayor Sergei Sobyanin has asked employers to allow third of its staff to work remotely. Russia had ordered a strict lockdown in March but began lifting restrictions as cases began to drop in May. Moscow, however, reimposed some tough measures last month. Russia now has the fourth-highest confirmed cases of coronavirus in the world.

Russia records highest daily surge in virus as Kremlin rejects lockdown

Russian cosmonauts set to blast off for the International Space Station said on Thursday it was too early to get a coronavirus vaccine touted by President Vladimir Putin.

“I’d personally say that I would not get vaccinated because I tread very carefully on this issue,” said Sergei Ryzhikov, the 46-year-old leader of the next expedition to the ISS in October.&nbsp;

The space mission of the next crew to the International Space Station (ISS), which will leave for the ISS aboard the Soyuz MS-17 spacecraft from the Baikonur cosmodrome in October, will last 177 days, Russian Cosmonaut Sergey Ryzhikov, the head of the crew, said on Thursday, though Roscosmos has said that the mission will last 186 days.

"According to the current plan, the duration of our expedition is 177 days. We are expected to return back [on Earth] on April 9 next year if nothing changes," Ryzhikov said at a press conference.

Meanwhile, More than 60 percent of Russian citizens are not ready to be vaccinated against the novel coronavirus to be able to go abroad if vaccination becomes a mandatory condition for travel, according to the results of a recent poll by the travel service website, Tutu.ru.

(With inputs from agencies)

Russian cosmonauts set to blast off for the International Space Station said on Thursday it was too early to get a coronavirus vaccine touted by President Vladimir Putin.

Russian cosmonauts set to blast off for the International Space Station said on Thursday it was too early to get a coronavirus vaccine touted by President Vladimir Putin. “I’d personally say that I would not get vaccinated because I tread very carefully on this issue,” said Sergei Ryzhikov, the 46-year-old leader of the next expedition to the ISS in October. The space mission of the next crew to the International Space Station (ISS), which will leave for the ISS aboard the Soyuz MS-17 spacecraft from the Baikonur cosmodrome in October, will last 177 days, Russian Cosmonaut Sergey Ryzhikov, the head of the crew, said on Thursday, though Roscosmos has said that the mission will last 186 days. "According to the current plan, the duration of our expedition is 177 days. We are expected to return back [on Earth] on April 9 next year if nothing changes," Ryzhikov said at a press conference. Meanwhile, More than 60 percent of Russian citizens are not ready to be vaccinated against the novel coronavirus to be able to go abroad if vaccination becomes a mandatory condition for travel, according to the results of a recent poll by the travel service website, Tutu.ru. (With inputs from agencies)

Cosmonauts say not ready to try Russia’s virus vaccine

Russian President Vladimir Putin on Tuesday offered to provide its coronavirus vaccine free-of-cost&nbsp;to United Nations staff all over the world. He made the proposal during his pre-recorded address to United Nations General Assembly. Putin called Russian-developed coronavirus vaccine Sputnik-V 'safe, reliable and effective'

"Russia is ready to provide the UN with all the necessary qualified assistance, in particular, we are offering to provide our vaccine, free of charge, for the voluntary vaccination of the staff of the UN and its offices. We have received requests from our UN colleagues in this respect, and we will respond to those," said Putin.

Sputnik-V vaccine has been developed by Gamaleya Institute in Russia. The vaccine has cleared Phase-2 trials. It is yet to clear Phase-3.

Although there have been claims from the Russian side that Sputnik-V prompts sufficient antibody response against coronavirus infection, critics remain skeptical about the vaccine. Mass trials of Sputnik-V vaccine have not been carried out but high ranking officials and ministers in the Russian Government have been given doses.

Also Read | <a href="https://www.wionews.com/world/covid-19-death-toll-in-united-states-passes-200000-trump-blames-china-at-unga-329553">COVID-19: Death toll in United States passes 200,000; Trump blames China at UNGA</a>

Putin's own daughter has also been administered the vaccine but which of his two daughters was given the vaccine was a mystery when the news broke.

In his UN speech, Putin said Russia was open to co-operation with respect to Sputnik-V vaccine.

"I would like to reiterate that we are completely open to partner relations and willing to cooperate. In this context, we are proposing to hold an online high-level conference shortly for countries interested in cooperation in the development of anti-coronavirus vaccines," he added

Putin outlined Russia`s active contribution to global and regional counter-COVID-19 efforts, saying the country provided assistance to most affected nations both bilaterally and within multilateral formats. He called on the need to "qualitatively strengthen" the capability of the World Health Organisation (WHO).

"...We first of all take into account the central coordinating role of the WHO, which is part of the UN system. We believe it essential to qualitatively strengthen WHO capability. This work has already begun, and Russia is genuinely motivated to engage in it," the Russian President remarked.

(With agency inputs)

Russian President Vladimir Putin on Tuesday offered to provide its coronavirus vaccine free-of-cost to United Nations staff all over the world. He made the proposal during his pre-recorded address to United Nations General Assembly.

Russian President Vladimir Putin on Tuesday offered to provide its coronavirus vaccine free-of-cost to United Nations staff all over the world. He made the proposal during his pre-recorded address to United Nations General Assembly. Putin called Russian-developed coronavirus vaccine Sputnik-V 'safe, reliable and effective' "Russia is ready to provide the UN with all the necessary qualified assistance, in particular, we are offering to provide our vaccine, free of charge, for the voluntary vaccination of the staff of the UN and its offices. We have received requests from our UN colleagues in this respect, and we will respond to those," said Putin. Sputnik-V vaccine has been developed by Gamaleya Institute in Russia. The vaccine has cleared Phase-2 trials. It is yet to clear Phase-3. Although there have been claims from the Russian side that Sputnik-V prompts sufficient antibody response against coronavirus infection, critics remain skeptical about the vaccine. Mass trials of Sputnik-V vaccine have not been carried out but high ranking officials and ministers in the Russian Government have been given doses. Also Read | COVID-19: Death toll in United States passes 200,000; Trump blames China at UNGA Putin's own daughter has also been administered the vaccine but which of his two daughters was given the vaccine was a mystery when the news broke. In his UN speech, Putin said Russia was open to co-operation with respect to Sputnik-V vaccine. "I would like to reiterate that we are completely open to partner relations and willing to cooperate. In this context, we are proposing to hold an online high-level conference shortly for countries interested in cooperation in the development of anti-coronavirus vaccines," he added Putin outlined Russia`s active contribution to global and regional counter-COVID-19 efforts, saying the country provided assistance to most affected nations both bilaterally and within multilateral formats. He called on the need to "qualitatively strengthen" the capability of the World Health Organisation (WHO). "...We first of all take into account the central coordinating role of the WHO, which is part of the UN system. We believe it essential to qualitatively strengthen WHO capability. This work has already begun, and Russia is genuinely motivated to engage in it," the Russian President remarked. (With agency inputs)

Russia offers to give free coronavirus vaccine for UN staff across globe

Russia's sovereign wealth fund said on Wednesday it will supply India's Dr. Reddy's Laboratories with 100 million doses of the Sputnik-V vaccine against COVID-19 once it receives regulatory approval in India.

<a href="https://www.wionews.com/india-news/covid-19-india-crosses-5-million-cases-with-90123-new-cases-327847">Also Read:&nbsp;India crosses 5 million COVID-19 cases with 90,123 new cases</a>

The Russian Direct Investment Fund (RDIF) added that it had agreed to cooperate on clinical trials and the distribution of the vaccine with the Indian firm.

Clinical trials of the Russian vaccine in India are expected to follow and to be held jointly with this firm, the source said. Both the trials and supply deal depend on domestic regulatory approval.

The Russian Direct Investment Fund (RDIF) has already inked vaccine supply deals with Kazakhstan, Brazil and Mexico and has reached a manufacturing partnership agreement with India to produce 300 million doses of the Sputnik-V vaccine there.

RDIF will announce the name of the Indian firm later on Wednesday, the source said.

Russia has billed Sputnik-V as the first vaccine against coronavirus to be registered in the world. Large-scale trials, known as Phase III, involving at least 40,000 people, were launched in Russia on August 26 but have yet to be completed.

Russia's sovereign wealth fund said on Wednesday it will supply India's Dr. Reddy's Laboratories with 100 million doses of the Sputnik-V vaccine against COVID-19 once it receives regulatory approval in India.

Russia's sovereign wealth fund said on Wednesday it will supply India's Dr. Reddy's Laboratories with 100 million doses of the Sputnik-V vaccine against COVID-19 once it receives regulatory approval in India. Also Read: India crosses 5 million COVID-19 cases with 90,123 new cases The Russian Direct Investment Fund (RDIF) added that it had agreed to cooperate on clinical trials and the distribution of the vaccine with the Indian firm. Clinical trials of the Russian vaccine in India are expected to follow and to be held jointly with this firm, the source said. Both the trials and supply deal depend on domestic regulatory approval. The Russian Direct Investment Fund (RDIF) has already inked vaccine supply deals with Kazakhstan, Brazil and Mexico and has reached a manufacturing partnership agreement with India to produce 300 million doses of the Sputnik-V vaccine there. RDIF will announce the name of the Indian firm later on Wednesday, the source said. Russia has billed Sputnik-V as the first vaccine against coronavirus to be registered in the world. Large-scale trials, known as Phase III, involving at least 40,000 people, were launched in Russia on August 26 but have yet to be completed.

Russia to sell COVID-19 vaccine to Indian firm after regulatory approval

Twenty-six scientists, most of them working at universities in Italy, have signed an open letter questioning the reliability of the data presented in the early-stage trial results of the Russian COVID-19 vaccine, named "Sputnik-V".

Addressing the editor of The Lancet, the international peer-reviewed medical journal in which Moscow's Gamaleya Institute published its early-stage trial results, the scientists said they saw patterns in the data that looked "highly unlikely".

The letter, published on the personal blog page of one of the signatories, said the Phase I/II trial results data showed multiple participants reporting identical antibody levels.

"On the ground of simple probabilistic evaluations the fact of observing so many data points preserved among different experiments is highly unlikely," the open letter said.

However, the scientists said they were basing their conclusions on summaries of the Russian trial result data, published in the journal, rather than the original data itself.

"In lack of the original numerical data, no conclusions can be definitively drawn on the reliability of the data presented, especially regarding the apparent duplications detected," the letter said.

The Gamaleya Institute, which developed the vaccine, rejected the critique.

"The published results are authentic and accurate and were examined by five reviewers at The Lancet," Denis Logunov, a deputy director at the institute, said in a statement.

He said his institute submitted the entire body of raw data on the trial results to The Lancet.

"We presented specifically the data that was produced (by the trial), not the data that is supposed to please Italian experts," Logunov said.

Naor Bar-Zeev, deputy director at John Hopkins Bloomberg School of Public Health, who peer reviewed the Russian data, defended his analysis of the research.

"Science must maintain a balance between incredulity, skepticism and trust. That trust is borne out through plausibility, repeatability and falsifiability."

"The results are plausible, and not very different to those seen with other AdV vectored products," he said.

The researchers had provided more detail than was needed for the review and responded to his questions "intelligently and in a matter-of-fact and confident but understated manner".

"Bottom line, I saw no reason to doubt the legitimacy of these results over others I have read and reviewed. But of course one can never know," he said in an email.

A spokeswoman for the Lancet said the journal had invited the study's authors to respond to the questions raised in the open letter. It was following the situation closely, she said.

Russia published results on Friday of its Phase I/II trial, which included 76 participants and was conducted in June-July this year. Participants developed a positive immune response and no serious side effects, the study's authors said.

A Phase III trial, involving 40,000 participants, was launched on Aug. 26. Around 31,000 people have already subscribed to take part, Health Minister Mikhail Murashko said.

Twenty-six scientists, most of them working at universities in Italy, have signed an open letter questioning the reliability of the data presented in the early-stage trial results of the Russian COVID-19 vaccine, named "Sputnik-V".

Twenty-six scientists, most of them working at universities in Italy, have signed an open letter questioning the reliability of the data presented in the early-stage trial results of the Russian COVID-19 vaccine, named "Sputnik-V". Addressing the editor of The Lancet, the international peer-reviewed medical journal in which Moscow's Gamaleya Institute published its early-stage trial results, the scientists said they saw patterns in the data that looked "highly unlikely". The letter, published on the personal blog page of one of the signatories, said the Phase I/II trial results data showed multiple participants reporting identical antibody levels. "On the ground of simple probabilistic evaluations the fact of observing so many data points preserved among different experiments is highly unlikely," the open letter said. However, the scientists said they were basing their conclusions on summaries of the Russian trial result data, published in the journal, rather than the original data itself. "In lack of the original numerical data, no conclusions can be definitively drawn on the reliability of the data presented, especially regarding the apparent duplications detected," the letter said. The Gamaleya Institute, which developed the vaccine, rejected the critique. "The published results are authentic and accurate and were examined by five reviewers at The Lancet," Denis Logunov, a deputy director at the institute, said in a statement. He said his institute submitted the entire body of raw data on the trial results to The Lancet. "We presented specifically the data that was produced (by the trial), not the data that is supposed to please Italian experts," Logunov said. Naor Bar-Zeev, deputy director at John Hopkins Bloomberg School of Public Health, who peer reviewed the Russian data, defended his analysis of the research. "Science must maintain a balance between incredulity, skepticism and trust. That trust is borne out through plausibility, repeatability and falsifiability." "The results are plausible, and not very different to those seen with other AdV vectored products," he said. The researchers had provided more detail than was needed for the review and responded to his questions "intelligently and in a matter-of-fact and confident but understated manner". "Bottom line, I saw no reason to doubt the legitimacy of these results over others I have read and reviewed. But of course one can never know," he said in an email. A spokeswoman for the Lancet said the journal had invited the study's authors to respond to the questions raised in the open letter. It was following the situation closely, she said. Russia published results on Friday of its Phase I/II trial, which included 76 participants and was conducted in June-July this year. Participants developed a positive immune response and no serious side effects, the study's authors said. A Phase III trial, involving 40,000 participants, was launched on Aug. 26. Around 31,000 people have already subscribed to take part, Health Minister Mikhail Murashko said.

‘Unlikely patterns in Russia vaccine data’: 26 scientists warn in open letter

Russia's "Sputnik-V" COVID-19 vaccine produced an antibody response in all participants in early-stage trials, according to results published on Friday by The Lancet medical journal that were hailed by Moscow as an answer to its critics.

Russian vaccine produces immune response, 100% of participants develop antibodies

sputnik-v-0

Sputnik V, News on Sputnik V, stories on Sputnik V, articles on Sputnik V, Sputnik V stories at Wion, Sputnik V news, Sputnik V latest news

sputnik v-0